| Direct Competitor Comparison | |
|---|
| AUXL | ABT | ACT | LLY | Industry |
|---|
| Market Cap: | 837.39M | 56.75B | 15.74B | 55.81B | N/A |
|---|
| Employees: | 526 | 91,000 | 17,700 | 38,350 | N/A |
|---|
| Qtrly Rev Growth (yoy): | -0.10 | 0.02 | 0.24 | 0.00 | 0.00 |
|---|
| Revenue (ttm):
| 387.85M | 39.97B | 6.29B | 22.60B | N/A |
|---|
| Gross Margin (ttm): | 0.80 | 0.62 | 0.47 | 0.79 | 0.00 |
|---|
| EBITDA (ttm): | 100.96M | 11.56B | 1.45B | 6.51B | N/A |
|---|
| Operating Margin (ttm):
| 0.21 | 0.22 | 0.13 | 0.22 | 0.00 |
|---|
| Net Income (ttm): | 79.53M | 6.11B | -60.30M | 4.63B | N/A |
|---|
| EPS (ttm): | 1.60 | 3.28 | -0.48 | 4.16 | N/A |
|---|
| P/E (ttm): | 10.70 | 11.21 | N/A | 12.47 | N/A |
|---|
| PEG (5 yr expected): | -4.46 | 1.55 | 1.02 | -5.72 | N/A |
|---|
| P/S (ttm): | 2.20 | 1.46 | 2.55 | 2.51 | N/A |
|---|
|
| ABT = Abbott Laboratories | | ACT = Actavis, Inc. | | LLY = Eli Lilly and Company | | Industry = Drug Related Products | |
| Biotechnology Companies Ranked By Sales | |
|---|
|
| Company | Symbol | Price | Change | Market Cap | P/E |
|---|
| Amgen Inc. | AMGN | 100.61 | -0.01 | 74.53B | 17.03 |
|---|
| Genentech, Inc. | "Private" |
|---|
| Biogen Idec Inc. | BIIB | 207.17 | -0.02 | 48.57B | 32.87 |
|---|
| Genzyme Corporation | "Private" |
|---|
| Merck Serono S.A. | "Private" |
|---|
| Gilead Sciences Inc. | GILD | 51.39 | -0.01 | 77.40B | 28.77 |
|---|
| MedImmune, L.L.C. | "Private" |
|---|
| Life Technologies Corporation | LIFE | 74.17 | -0.00 | 12.75B | 31.40 |
|---|
| Teva Pharmaceutical Industries Limited | TEVA | 39.38 | -0.01 | 33.42B | 19.66 |
|---|
| Sandoz International GmbH | "Private" |
|---|
|
| Generic Drugmakers Ranked by Sales | |
|---|
|
| Company | Symbol | Price | Change | Market Cap | P/E |
|---|
| Actavis, Inc. | ACT | 124.25 | -0.01 | 15.74B | N/A |
|---|
| Ranbaxy Laboratories Limited | "Private" |
|---|
| Mylan, Inc. | MYL | 31.45 | -0.01 | 11.88B | 21.01 |
|---|
| Pfizer Inc. | PFE | 29.48 | 0.00 | 207.05B | 14.11 |
|---|
| Johnson & Johnson | JNJ | 85.82 | -0.01 | 238.28B | 23.31 |
|---|
| GlaxoSmithKline plc | GSK | 51.94 | -0.01 | 124.93B | 18.98 |
|---|
| Sanofi | SNY | 53.82 | -0.01 | 141.50B | 26.53 |
|---|
| Novartis AG | NVS | 72.51 | -0.01 | 176.97B | 18.40 |
|---|
| Roche Holding AG | RHHBY | 62.20 | -0.00 | 211.10B | 20.82 |
|---|
| AstraZeneca PLC | AZN | 50.56 | -0.01 | 62.81B | 11.18 |
|---|
|
| Drugmakers Ranked By Sales | |
|---|
|
| Company | Symbol | Price | Change | Market Cap | P/E |
|---|
| Abbott Laboratories | ABT | 36.79 | -0.02 | 56.75B | 11.21 |
|---|
| Bristol-Myers Squibb Company | BMY | 46.56 | -0.01 | 75.72B | 52.73 |
|---|
|
| News on Direct Competitors | |
|---|
- ACT
- Lundbeck fined ?94m for 'pay for delay' deals to rivals at Financial Times Wed 12:46pm
- ACT
- InPlay: Actavis And Kissei file lawsuits against sandoz and hetero for infringement of rapaflo patent Briefing.com Wed 8:04am
- ACT
- Actavis And Kissei File Lawsuits Against Sandoz And Hetero For Infringement Of Rapaflo® Patent PR Newswire Wed 8:00am
- LLY
- Lilly and Incyte Announce Baricitinib Efficacy and Safety Data from the Open-Label, Long-Term Extension of the Phase 2b JADA Study in Patients with Rheumatoid Arthritis at noodls Thu, Jun 13
- LLY
- Lilly and Incyte Announce Baricitinib Efficacy and Safety Data from the Open-Label, Long-Term Extension of the Phase 2b JADA Study in Patients with Rheumatoid Arthritis at noodls Thu, Jun 13
- ACT
- Actavis and Medicines360 Announce Partnership to Advance Women's Access to Affordable IUDs at noodls Tue, Jun 11
- ACT
- Columbia Laboratories Reports Fourth Quarter and Year-End 2012 Financial Results at noodls Thu, Mar 14
- ABT
- Abbott Declares 357th Consecutive Quarterly Dividend at noodls Fri, Feb 15
- LLY
- QIAGEN enters into broad collaboration agreement with Lilly for the development and commercialization of companion diagnostics at noodls Thu, Feb 14
- LLY
- LILLY (ELI) & COMPANY - Amyvid Approved in European Union at noodls Wed, Jan 16
- ABT
- Abbott Initiates Clinical Trial of Absorb™ in the United States at noodls Wed, Jan 9
- ABT
- New Abbott Test Available in Europe Provides Novel Tool to Aid Doctors in Evaluating Potential Heart Attacks at noodls Wed, Jan 9
- ABT
- Abbott Announces FDA Approval and U.S. Launch of Next-Generation XIENCE Xpedition™ Drug Eluting Stent System at noodls Thu, Jan 3
- ABT
- Abbott Completes Separation of Research-Based Pharmaceuticals Business at noodls Wed, Jan 2
- LLY
- LILLY (ELI) & COMPANY - LLY Sets Dates for Financial Guidance & Q4 2012 Results at noodls Tue, Dec 18
All Headlines for these symbols... Currency in USD. | |
|
0.98%